(DNTH) Dianthus Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.850m USD | Total Return: 371% in 12m
Avg Turnover: 42.4M
Warnings
Share dilution 34.2% YoY
High Debt while negative Cash Flow
Beneish M-Score 0.63 > -1.5 - likely earnings manipulation
Altman Z'' -5.59 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader, Confidence
Dianthus Therapeutics (DNTH) is a clinical-stage biotechnology company focused on developing monoclonal antibodies and fusion proteins for severe autoimmune conditions. Its primary candidate, claseprubart, targets the C1s complement protein with an engineered extended half-life to improve dosing efficiency. The company’s pipeline also includes DNTH212, which utilizes a dual-action mechanism to suppress B cell function and reduce Type 1 interferon production.
The biotechnology sector often requires significant capital expenditure and long-duration clinical trials before achieving regulatory approval. Dianthus operates under a research-intensive business model, prioritizing high-selectivity biologics to minimize off-target effects in the immune system. For a comprehensive look at the companys valuation metrics, you can explore the data available on ValueRay. Founded in 2019 and based in New York, the company continues to advance its candidates through early to mid-stage clinical development.
- Claseprubart clinical trial data readouts for generalized myasthenia gravis drive valuation
- Regulatory progress of DNTH212 in pDC-mediated autoimmune diseases impacts market sentiment
- Long-term capital requirements for pipeline development dictate future equity dilution risk
- Strategic partnerships or acquisition interest in complement inhibitor technology influences pricing
- Competitive landscape shifts within the monoclonal antibody space for severe autoimmunity
| Net Income: -11.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 15.63 > 1.0 |
| NWC/Revenue: 81.0k% < 20% (prev 3.89k%; Δ 77.1k% < -1%) |
| CFO/TA -0.10 > 3% & CFO -130.3m > Net Income -11.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 29.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.0m) vs 12m ago 34.20% < -2% |
| Gross Margin: 94.31% > 18% (prev 0.93%; Δ 9.34k% > 0.5%) |
| Asset Turnover: 0.17% > 50% (prev 1.87%; Δ -1.70% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 1.12b - Total Current Liabilities 38.3m) / Total Assets 1.25b |
| B: -0.30 (Retained Earnings -377.6m / Total Assets 1.25b) |
| C: -0.24 (EBIT TTM -187.8m / Avg Total Assets 797.7m) |
| D: -8.30 (Book Value of Equity -378.1m / Total Liabilities 45.6m) |
| Altman-Z'' = -5.59 = D |
| DSRI: 6.41 (Receivables 1.31m/1.00m, Revenue 1.34m/6.52m) |
| GMI: 0.99 (GM 94.31% / 93.29%) |
| AQI: 0.46 (AQ_t 0.10 / AQ_t-1 0.22) |
| SGI: 0.20 (Revenue 1.34m / 6.52m) |
| TATA: 0.10 (NI -11.3m - CFO -130.3m) / TA 1.25b) |
| Beneish M = 0.63 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 89.63 with a total of 493,535 shares traded.
Over the past week, the price has changed by +0.37%,
over one month by -5.27%,
over three months by +64.16% and
over the past year by +371.02%.
Dianthus Therapeutics has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy DNTH.
- StrongBuy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 125.8 | 40.4% |
P/B = 4.0372
Revenue TTM = 1.34m USD
EBIT TTM = -187.8m USD
EBITDA TTM = -187.4m USD
Long Term Debt = 965k USD (estimated: total debt 1.36m - short term 399k)
Short Term Debt = 399k USD (from shortTermDebt, last quarter)
Debt = 1.36m USD (from shortLongTermDebtTotal, last quarter) (leases 1.36m already included)
Net Debt = -1.11b USD (calculated: Debt 1.36m - CCE 1.11b)
Enterprise Value = 3.74b USD (4.85b + Debt 1.36m - CCE 1.11b)
Interest Coverage Ratio = unknown (Ebit TTM -187.8m / Interest Expense TTM 0.0)
EV/FCF = -28.66x (Enterprise Value 3.74b / FCF TTM -130.5m)
FCF Yield = -3.49% (FCF TTM -130.5m / Enterprise Value 3.74b)
FCF Margin = -9.77k% (FCF TTM -130.5m / Revenue TTM 1.34m)
Net Margin = -847.5% (Net Income TTM -11.3m / Revenue TTM 1.34m)
Gross Margin = 94.31% ((Revenue TTM 1.34m - Cost of Revenue TTM 76.0k) / Revenue TTM)
Gross Margin QoQ = 83.59% (prev none%)
Tobins Q-Ratio = 3.00 (Enterprise Value 3.74b / Total Assets 1.25b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.36m)
Taxrate = 21.0% (US default 21%)
NOPAT = -148.4m (EBIT -187.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 29.25 (Total Current Assets 1.12b / Total Current Liabilities 38.3m)
Debt / Equity = 0.00 (Debt 1.36m / totalStockholderEquity, last quarter 1.20b)
Debt / EBITDA = 5.92 (negative EBITDA) (Net Debt -1.11b / EBITDA -187.4m)
Debt / FCF = 8.51 (negative FCF - burning cash) (Net Debt -1.11b / FCF TTM -130.5m)
Total Stockholder Equity = 636.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.42% (Net Income -11.3m / Total Assets 1.25b)
RoE = -1.12% (Net Income TTM -11.3m / Total Stockholder Equity 1.01b)
RoCE = -18.51% (EBIT -187.8m / Capital Employed (Equity 1.01b + L.T.Debt 965k))
RoIC = -14.29% (negative operating profit) (NOPAT -148.4m / Invested Capital 1.04b)
WACC = 9.74% (E(4.85b)/V(4.85b) * Re(9.74%) + D(1.36m)/V(4.85b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 185.6%
[DCF] Fair Price = unknown (Cash Flow -130.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.45 | # QB: 1
Revenue Correlation: -33.69 | Revenue CAGR: -15.80% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.91 | Chg30d=+18.23% | Revisions=+20% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-1.02 | Chg30d=+9.40% | Revisions=+20% | Analysts=8
EPS current Year (2026-12-31): EPS=-3.90 | Chg30d=+16.23% | Revisions=+20% | GrowthEPS=+7.2% | GrowthRev=-42.8%
EPS next Year (2027-12-31): EPS=-4.63 | Chg30d=+9.51% | Revisions=+20% | GrowthEPS=-18.7% | GrowthRev=+36.1%
[Analyst] Revisions Ratio: +20%